X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims for the development of long-acting implants that deliver antisense oligonucleotides using Celanese VitalDose® drug delivery platform and Secarna’s proprietary ASO drug discovery and development platform.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Secarna Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 20, 2024
Details:
iDose® TR (Travoprost Intracameral Implant) is a prostaglandin analog. It s indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Glaukos
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
Glaukos will supply its VitalDose® Drug Delivery Platform for use as a component in Glaukos’ iDose® TR (travoprost), a micro-invasive intraocular implant designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Glaukos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 05, 2023
Details:
VitalDose® EVA drug delivery platform will be used in the development of Alessa Therapeutics’ proprietary localized drug delivery technology. The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Alessa Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
